Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
2.
Nat Commun ; 10(1): 5785, 2019 12 19.
Article in English | MEDLINE | ID: mdl-31857578

ABSTRACT

Uterine adenomyosis is a benign disorder that often co-occurs with endometriosis and/or leiomyoma, and impairs quality of life. The genomic features of adenomyosis are unknown. Here we apply next-generation sequencing to adenomyosis (70 individuals and 192 multi-regional samples), as well as co-occurring leiomyoma and endometriosis, and find recurring KRAS mutations in 26/70 (37.1%) of adenomyosis cases. Multi-regional sequencing reveals oligoclonality in adenomyosis, with some mutations also detected in normal endometrium and/or co-occurring endometriosis. KRAS mutations are more frequent in cases of adenomyosis with co-occurring endometriosis, low progesterone receptor (PR) expression, or progestin (dienogest; DNG) pretreatment. DNG's anti-proliferative effect is diminished via epigenetic silencing of PR in immortalized cells with mutant KRAS. Our genomic analyses suggest that adenomyotic lesions frequently contain KRAS mutations that may reduce DNG efficacy, and that adenomyosis and endometriosis may share molecular etiology, explaining their co-occurrence. These findings could lead to genetically guided therapy and/or relapse risk assessment after uterine-sparing surgery.


Subject(s)
Adenomyosis/genetics , Endometriosis/genetics , Nandrolone/analogs & derivatives , Proto-Oncogene Proteins p21(ras)/genetics , Adenomyosis/complications , Adenomyosis/therapy , Adult , Cell Proliferation/drug effects , Cell Proliferation/genetics , DNA Mutational Analysis , Endometriosis/complications , Endometriosis/therapy , Endometrium/pathology , Endometrium/surgery , Female , High-Throughput Nucleotide Sequencing , Humans , Hysterectomy , Middle Aged , Mutation , Myometrium/pathology , Myometrium/surgery , Nandrolone/pharmacology , Nandrolone/therapeutic use , Receptors, Progesterone/genetics , Receptors, Progesterone/metabolism , Treatment Outcome , Young Adult
3.
Cancer Sci ; 110(8): 2643-2651, 2019 Aug.
Article in English | MEDLINE | ID: mdl-31222839

ABSTRACT

Scirrhous-type gastric cancer (SGC) is one of the most intractable cancer subtypes in humans, and its therapeutic targets have been rarely identified to date. Exploration of somatic mutations in the SGC genome with the next-generation sequencers has been hampered by markedly increased fibrous tissues. Thus, SGC cell lines may be useful resources for searching for novel oncogenes. Here we have conducted whole exome sequencing and RNA sequencing on 2 SGC cell lines, OCUM-8 and OCUM-9. Interestingly, most of the mutations thus identified have not been reported. In OCUM-8 cells, a novel CD44-IGF1R fusion gene is discovered, the protein product of which ligates the amino-terminus of CD44 to the transmembrane and tyrosine-kinase domains of IGF1R. Furthermore, both CD44 and IGF1R are markedly amplified in the OCUM-8 genome and abundantly expressed. CD44-IGF1R has a transforming ability, and the suppression of its kinase activity leads to rapid cell death of OCUM-8. To the best of our knowledge, this is the first report describing the transforming activity of IGF1R fusion genes. However, OCUM-9 seems to possess multiple oncogenic events in its genome. In particular, a novel BORCS5-ETV6 fusion gene is identified in the OCUM-9 genome. BORCS5-ETV6 possesses oncogenic activity, and suppression of its message partially inhibits cell growth. Prevalence of these novel fusion genes among SGC awaits further investigation, but we validate the significance of cell lines as appropriate reagents for detailed genomic analyses of SGC.


Subject(s)
Adenocarcinoma, Scirrhous/genetics , Oncogenes/genetics , Stomach Neoplasms/genetics , 3T3 Cells , Adenocarcinoma, Scirrhous/pathology , Animals , Cell Line , Cell Line, Tumor , Cell Proliferation/genetics , HEK293 Cells , Humans , Hyaluronan Receptors/genetics , Membrane Proteins/genetics , Mice , Mutation/genetics , Receptor, IGF Type 1/genetics , Stomach/pathology , Stomach Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...